Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Appointed director
CC transcript

BIOCRYST PHARMACEUTICALS INC (BCRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "BioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update"
07/11/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/30/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
06/02/2023 4 MILANO VINCENT (Director) has filed a Form 4 on BIOCRYST PHARMACEUTICALS INC
Txns: Granted 680 shares @ $8.27, valued at $5.6k
06/02/2023 4 LEVIN ALAN G (Director) has filed a Form 4 on BIOCRYST PHARMACEUTICALS INC
Txns: Granted 1,360 shares @ $8.27, valued at $11.2k
06/02/2023 4 HEGGIE THERESA (Director) has filed a Form 4 on BIOCRYST PHARMACEUTICALS INC
Txns: Granted 680 shares @ $8.27, valued at $5.6k
05/08/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/03/2023 8-K Quarterly results
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/18/2023 8-K Quarterly results
04/05/2023 4 Thackray Helen M. (Chief R&D Officer) has filed a Form 4 on BIOCRYST PHARMACEUTICALS INC
Txns: Sold 7,000 shares @ $8.29, valued at $58k
03/23/2023 4 Stonehouse Jon P (President & CEO) has filed a Form 4 on BIOCRYST PHARMACEUTICALS INC
Txns: Exercised 31,055 options to buy @ $3.22, valued at $100k
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
03/02/2023 4 MILANO VINCENT (Director) has filed a Form 4 on BIOCRYST PHARMACEUTICALS INC
Txns: Granted 635 shares @ $8.85, valued at $5.6k
03/02/2023 4 INGRAM ROBERT ALEXANDER (Director) has filed a Form 4 on BIOCRYST PHARMACEUTICALS INC
Txns: Granted 2,259 shares @ $8.85, valued at $20k
03/02/2023 4 HEGGIE THERESA (Director) has filed a Form 4 on BIOCRYST PHARMACEUTICALS INC
Txns: Granted 635 shares @ $8.85, valued at $5.6k
03/02/2023 4 LEVIN ALAN G (Director) has filed a Form 4 on BIOCRYST PHARMACEUTICALS INC
Txns: Granted 1,271 shares @ $8.85, valued at $11.2k
02/27/2023 10-K Annual Report for the period ended December 31, 2022
02/14/2023 SC 13G/A BAKER BROS. ADVISORS LP reports a 10% stake in BioCryst Pharmaceuticals, Inc.
02/06/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/03/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/02/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/02/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/09/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "BioCryst Announces Preliminary Full Year 2022 ORLADEYO® Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance",
"BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases"
12/21/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/21/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/21/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/21/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/21/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/21/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/19/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy